Skip to main content

Table 4 Acute and late toxicities

From: A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer

 

Acute

Late

G1

G2

G3

G1

G2

G3

RTOG

            

 GU

23

(41.8%)

5

(9.1%)

0

(0.0%)

27

(49.1%)

7

(12.7%)

1

(1.8%)

 GI

13

(23.6%)

6

(10.9%)

0

(0.0%)

17

(30.9%)

4

(7.3%)

1

(1.8%)

Miction pain

5

(9.1%)

1

(1.8%)

0

(0.0%)

12

(21.8%)

0

(0.0%)

0

(0.0%)

Frequency

19

(34.5%)

3

(5.5%)

0

(0.0%)

16

(29.1%)

6

(10.9%)

1

(1.8%)

Urinary incontinence

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Retention

8

(14.5%)

2

(3.6%)

0

(0.0%)

6

(10.9%)

2

(3.6%)

0

(0.0%)

Hematuria

0

(0.0%)

0

(0.0%)

0

(0.0%)

10

(18.2%)

0

(0.0%)

1

(1.8%)

Stricture

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Proctitis

6

(10.9%)

2

(3.6%)

0

(0.0%)

3

(5.5%)

0

(0.0%)

0

(0.0%)

Fecal incontinence

2

(3.6%)

1

(1.8%)

0

(0.0%)

1

(1.8%)

0

(0.0%)

0

(0.0%)

Diarrhea

7

(12.7%)

1

(1.8%)

0

(0.0%)

3

(5.5%)

0

(0.0%)

0

(0.0%)

Rectal hemorrhage

5

(9.1%)

2

(3.6%)

0

(0.0%)

15

(27.3%)

5

(9.1%)

1

(1.8%)

  1. GU, genitourinary toxicity; GI, gastrointestinal toxicity
  2. RTOG, Radiation Therapy Oncology Group